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Background: Cytochrome P450s (CYPs) are important heme-containing proteins, well known for their monooxygenase
reaction. The human cytochrome P450 4X1 (CYP4X1) is categorized as “orphan” CYP because of its unknown function.
In recent studies it is found that this enzyme is expressed in neurovascular functions of the brain. Also, various studies
have found the expression and activity of orphan human cytochrome P450 4X1 in cancer. It is found to be a potential
drug target for cancer therapy. However, three-dimensional structure, the active site topology and substrate specificity
of CYP4X1 remain unclear.
Methods: In the present study, the three-dimensional structure of orphan human cytochrome P450 4X1 was
generated by homology modeling using Modeller 9v8. The generated structure was accessed for geometrical
errors and energy stability using PROCHECK, VERFIY 3D and PROSA. A molecular docking analysis was carried out
against substrates arachidonic acid and anandamide and the docked substrates were predicted for drug-likeness,
ADME-Tox parameters and biological spectrum activity.
Results: The three-dimensional model of orphan human cytochrome P450 4X1 was generated and assessed with various
structural validation programmes. Docking of orphan human cytochrome P450 4X1 with arachidonic acid revealed that
TYR 112, ALA 126, ILE 222, ILE 223, THR 312, LEU 315, ALA 316, ASP 319, THR 320, PHE 491 and ILE 492 residues were
actively participating in the interaction, while docking of CYP4X1 with anandamide showed that TYR 112, GLN 114, PRO
118, ALA 126, ILE 222, ILE 223, SER 251, LEU 315, ALA 316 and PHE 491 key residues were involved in strong interaction.
Conclusion: From this study, several key residues were identified to be responsible for the binding of arachidonic acid
and anandamide with orphan human cytochrome P450 4X1. Both substrates obeyed Lipinski rule of five in drug-likeness
test and biological spectrum prediction showed anticarcinogenic activity. Compared to anandamide, arachidonic acid
showed strong interaction with cytochrome P450 4X1 and also less health effect in certain human system in ADME-Tox
prediction. These findings provide useful information on the biological role and structure-based drug design of orphan
human cytochrome P450 4X1.
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Cytochromes P450 are a super family of heme-thiolate
proteins which are involved in the oxidative metabolism
of both foreign and endogenous compounds [1]. The
P450 enzymes are divided into 18 families and 43 sub-
families. The human P450s can also be divided based on
their ability to metabolize xenobiotic compounds: sterols,Correspondence: sureshkumar@ukm.edu.my
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orphans [2]. About 1/4 of the human P450 enzymes are
considered to be “orphans” because, functional informa-
tion, expression patterns, and regulation are still largely
unknown. The orphan enzymes are mostly found in fam-
ilies 1–4, with the largest number found in the P450 4
family [3-5].
CYP4X1 (cytochrome P450, family 4, subfamily X, poly-
peptide 1) is a protein which in humans is encoded by
CYP4X1 gene and is considered as one of such “orphan”s an Open Access article distributed under the terms of the Creative Commons
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P450 ABXZ gene cluster on chromosome 1. The gene has
12 exons and the predicted protein has 509 amino acids
[6]. The tissue distribution of human CYP4X1 is reported
to be predominantly found in adult human skeletal
muscle, trachea, and aorta [7]. Recent report suggests that
CYP4X1 is expressed in brain and in the liver [8,9]. It is
involved in drug metabolism and synthesis of cholesterol,
steroids and other lipids. Members of the cytochrome
P450 4F subfamily are known to primarily oxidize en-
dogenous compounds, for example, fatty acids and arachi-
donic acid derivatives [10]. The metabolic capabilities of
CYP4X1 are largely unknown, yet a recent study has iden-
tified arachidonic acid derivatives to have been implicated
in a large number of physiologically important processes.
A number of P450s, primarily from subfamilies 2C, 2J, 4A
and 4F, are known to oxidize arachidonic acid which has
been implicated as important signaling mediator. The
arachidonic acid derivative anandamide (arachidonoyl
ethanol amide) is a natural endocannabinoid found in
most human tissues, and acts as an important signaling
mediator in neurological, immune and cardiovascular
functions. Anandamide (arachidonoyl ethanol amide)
has emerged as an important signaling molecule in the
neurovascular cascade [11].
Human CYP4X1 amino acid sequence has been iden-
tified recently but the three-dimensional structure of
this protein is not yet known. Earlier experimental
studies of CYP4X1 proposed that arachidonic acid and
its derivative anandamide can act as possible substrates
[12]. However, to date information on the structure and
ligand binding site is not available for CYP4X1. Through
homology modeling it is possible to generate realistic
model comparable to experimental structures and through
docking studies substrate binding energies and import-
ant key residues involved in substrate binding can be
found. Many Computer-Aided Drug Design (CADD)
methodologies have been carried out previously for find-
ing suitable drug target [13-19]. In the present work,
three-dimensional model of CYP4X1 was constructed
using homology modeling and energy minimization was
done to refine the model. After that, arachidonic acid and
anandamide were docked into the active sites of the
CYP4X1 model. The interaction between CYP4X1 and
substrates helped in finding energetically favorable
binding sites and the key residues responsible for sub-
strate specificity.Methods
Sequence retrieval
The sequence of human CYP4X1 protein in FASTA for-
mat was retrieved from Uniprot Knowledge base (http://
www.uniprot.org/) of accession number Q8N118.Sequence alignment and homology modeling
For the template selection, PSI-BLAST search was used
against Protein Data Bank (PDB) and top ranked six
templates (1TQN, 3CZH, 2HI4, 3NA0, 3K9V, 3E4E)
were selected for the model building. The templates and
target sequence were aligned by using Clustal Omega
[20] with default parameters and observed for conserved
sequence. Further, the aligned sequence was used as the
input to generate homology model of CYP4X1 using
Modeller 9v5 [21]. The coordinates for heme were ob-
tained from the template 1TQN and positioned as in the
template.
Energy minimization and structural validation
The constructed CYP4X1 model was further refined by
energy minimization using YASARA package [22], and
the resulting model was subjected to structural quality
assessment. PROCHECK and VERIFY 3D were used for
geometric evaluation. The PROSA program was used to
assess the energy of residue-residue interaction using a
distance-based pair potential and the energy was trans-
formed to a score called Z-score. Residues with negative
Z-score indicate reasonable side-chain interactions.
Binding site analysis
ConSurf was used for identification of the functional re-
gions in the protein. The degree of conservation of the
amino acid sites among homologues protein with similar
sequences was estimated. The conservation scores were
depicted onto the molecular surface of the orphan hu-
man cytochrome P450 4X1 to reveal the patches with
highly conserved residues that are often important for
biological function.
Ligand optimization
The possible substrates like arachidonic acid and its de-
rivative anandamide were downloaded from the PubChem
in Structure Data Format (SDF). Conversion of SDF to
Protein Data Bank (PDB) format was carried out using
Open Babel program [23]. The MMFF94 force field was
used for energy minimization of ligand molecules [24].
Gasteiger partial charges were added to the ligand atoms,
non-polar hydrogen atoms were merged and rotatable
bonds were defined. Ligand geometries and electric prop-
erties were calculated using MOPAC2009 [25].
Molecular docking
Docking calculations were carried out using DockingSer-
ver [26] to compute the free energy of binding on pro-
tein model. Essential hydrogen atoms, Kollman united
atom type charges and solvation parameters were added
with the aid of Auto Dock tools [27]. Affinity (grid)
maps of 60X60X60Å grid points and 0.375 Å spacing
were generated using the Auto grid program. Auto Dock
Figure 1 Multiple alignment of CYP4X1 with templates. The target CYP4X1 (Q8N118) and six templates (1TQN, 3CZH, 2HI4, 3NA0, 3K9V, 3E4E)
were aligned using ClustalO program. The red color indicates conserved residues and yellow colour indicates a semi-consereved substitution. The
signature motifs are shown in the box. The alignment figure was prepared using ESpript 2.2.
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tions were used in the calculation of the Van der Waals
and the electrostatic terms respectively. Docking simula-
tions were performed using the Lamarckian Genetic Al-
gorithm (LGA) and the Solis and Wets local search
method. Initial position, orientation and torsions of the
ligand molecules were set randomly and all rotatable
torsions were released during docking. Each docking ex-
periment was derived from 10 different runs that wereFigure 2 Structural Quality Assessment. (A) Ramachandran plot of orph
in favored, allowed and outlier regions. (B) PROSA Z-score with respect toset to terminate after a maximum of 250000 energy eval-
uations. During the search population size of 150, trans-
lational step of 0.2 Å and quaternion and torsion steps
of 5 were applied.
Prediction of drug-likeness, ADME-Tox and biological
spectrum activity
The substrates arachidonic acid and anandamide were
subjected drug-likeness prediction using Lipinski rule ofan cytochrome P450 4X1 protein showing the distribution of residues
residue. (C) Q-Mean score.
Figure 3 Homology model and functional region prediction of CYP4X1. (A) Ribbon schematic representations of the homology model of
CYP4X1. Major helices are labeled. (B) Identification functional region of CYP4X1 using ConSurf. The colour-coding bar shows the colouring
scheme. Conserved amino acids are coloured bordeaux, residues with average conservation by white, and variable amino acids by turquoise.
Figure 4 2D structures of substrates. (A) Arachidonic acid.
(B) Anandamide.




The amino acid sequence of cytochrome P450 4X1 was
retrieved from UniProt database and subjected to trans-
membrane prediction using PHD and TMHMM 2.0
servers. The trans-membrane domain was predicted be-
tween 13–30 residues. The amino acid sequence of
CYP4X1 was queried against Protein Data Bank (PDB)
using PSI-Blast with five iterations. PSI-Blast analysis
showed that the alignment between target and templates
was below 30%. Under this circumstance, use of the mul-
tiple templates could provide more reliable structure mod-
eling. Hence, best six templates (1TQN, 3CZH, 2HI4,
3NA0, 3K9V, 3E4E) were selected and the selected tem-
plate sequence and target sequence (CYP4X1) were sub-
jected to multiple alignments using Clustal Omega with
default parameters. The alignment between targets and
templates were examined for sequence conservation and
signature motifs. The structural motifs were WxxxR in
the C helix, ExxR in the K helix and essential one
FxxGxxxCxG in L helix. Characteristic motif for the CYP
super family, which includes conserved cystine residue
that ligates to the Fe of the heme was observed (Figure 1).
Several signature motifs were conserved for CYP4X1
which is in agreement with previous findings [15,28]. The
conservation of sequence and signature motifs elucidates
that model based on this alignment is reliable. In the avail-
able template, the first 20 residues of the N-terminal were
deleted in order to facilitate its crystallization. Since the
N-terminus does not affect the substrate binding, the cor-
responding first 20 residues were not modeled in the
CYP4X1 model.Structure analysis
The alignment between templates and target sequence
were submitted to Modeller for the construction of hom-
ology model of CYP4X1. The loops were modeled through
the server ModLoop and subjected to energy minimization
using YASARA package. Energy minimization was per-
formed by YAMBER force field implemented in YASARA
package to get optimized model structure having the initial
energy of 72759.7 kJ/mol to a final energy of −247540.1 kJ/
mol. The energy minimized homology model of CYP4X1
was subjected to several structural validation programs like
PROCHECK, VERIFY 3D, QMEAN, PROSA, and PROVE.
The PROCHECK [29] analysis based on Ramachandran
plot provides an idea on the stereo chemical quality of the
protein model. It highlights regions of the proteins which
appear to have unusual geometry and provides an overall
assessment of the structure. The PROCHECK evaluation
showed the residues in most favored regions as 81.9%, resi-
dues in additional allowed regions as 14.8%, residues in
generously allowed regions as 2.6% and residues in
Table 1 Docking of CYP4X1 with selected ligands












Arachidonic acid −7.76 2.05 −10.87 +0.03 −10.84 813.954
Anandamide −5.76 59.98 −10.53 −0.03 −10.57 1042.601
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quality model, the residues located in the core and
allowed regions should be over 90% which is the case
for the model presented here (since 81.4% + 14.8% =
96.2%). In order to check the native protein folding en-
ergy of the model, PROSA II [30] analysis was made
and mean force potentials and averaged over all resi-
dues in the structure were determined. The PROSA II
analysis showed Z-score of −8.33 (Figure 2B), and
PROVE [31] analysis showed average Z-score of 0.97
and Z-score RMS value of 23.24. QMEAN [32] is a
scoring function of a linear combination of six struc-
tural descriptors with the score ranging between 0 and
1 and higher value reflecting a better quality of input
model. The QMEAN score of the present model is
0.517 (Figure 2C). From the results of entire structural
validation program it is inferred that the homology
modeled protein is reliable for further study.Figure 5 Interaction of CYP4X1 with substrates. (A) Arachidonic
acid and (B) Anandamide. Key residues are labeled. Substrates are
shown in green stick.The final model was deposited in Protein Model
Database (PMDB) [33] and it is available under ID:
PM0079202. The overall topology of homology model
of CYP4X1 consists of twelve helices, namely, A-L, five
antiparallel beta sheets and their connecting loops. The
heme is positioned between two structurally conserved
helices, I and L (Figure 3A). Highly conserved thero-
nine residue is located in the middle of helix I as seen
in many available mammalian CYP structures. This
conserved residue has been suggested to participate in
the proton delivery and play an important role in the
dioxygen bond cleavage during catalytic cycle [34].
Binding site prediction
ConSurf [35] was used to characterize the functional re-
gions in the protein. It identifies by considering the de-
gree of conservation of the amino acid sites among their
sequence homologues. The conservation grades were pro-
jected on the molecular surface of the CYP4X1 protein to
reveal the patches with highly conserved residues that are
often important for biological function. The surface resi-
dues with the most conserved amino acids are shown col-
ored in bordeaux, residues with average conservation in
white and variable amino acids in turquoise in the protein
structure in Figure 3B.
Predicting ligand binding sites can reduce the con-
formational space of docking and also can provide in-
sights into their molecular functions.
Molecular docking
In order to understand enzyme-substrate interaction and
to determine the key residues responsible for interaction,
the model of CYP4X1 was docked with selected sub-
strates using DockingServer. DockingServer integrates a
number of popular software like Auto Dock and
MOPAC for accurate ligand geometry optimization, en-
ergy minimization, charge calculation, docking calcula-
tion and protein-ligand complex representation. The
calculated free energy of binding of CYP4X1 with ara-
chidonic acid (Figure 4A) and anandamide (Figure 4B)
were −7.76 and −5.76 kcal/mol respectively (Table 1).
The negative and low value of free energy of binding
indicates a strong favorable bond between CYP4X1 and
arachidonic acid in most favorable conformations.
Docking of CYP4X1 with arachidonic acid revealed that
major residues involved were TYR 112, ALA 126, ILE
222, ILE 223, THR 312, LEU 315, ALA 316, ASP 319,




Arachidonic acid O1 [3.81]- GLN114 C4 [3.87] - TYR112 C8 [3.80]- GLN114
C17 [2.99] - ILE223 C13 [3.35]- GLN114
C14 [3.51] - ILE223 C18 [3.77] - GLN114
C19 [3.80] - ILE223 C4 [3.83] - GLN114
C12 [3.29] - PHE247 O2 [3.49]- ALA126
C15 [3.89] - PHE247 O2 [3.53] - LEU315
C17 [3.40] - LEU315 C6 [3.78] - SER385
C14 [3.27]- LEU315
C10 [3.53] - LEU315
C11[3.43] - LEU315
C20 [3.60]-LEU315
C19 [3.41] - PHE491
C16 [3.69]-PHE491
C6 [3.40] - PHE491
C9 [3.70] - PHE491
C5 [3.70] - PHE491
C2 [3.38] – PHE491
C4 [3.51] – PHE491
Anandamide C16 [3.25] -TYR112 C16 [3.86] -TYR112
C1 [3.43] -LEU121 C13 [3.51]-GLN114
C8 [3.70] -LEU121 C10 [3.89] -GLN114
C3 [3.89] - LEU121 C9 [3.61]-GLN114
C2 [3.81] -LEU121 C21 [3.24] -GLN114
C4 [3.43] -LEU121 C19 [3.09] -GLN114
C1 [3.78] -ALA126 O1 [3.24]- ALA126
C4 [3.48] -ALA126 O2 [3.36]- PHE491
C18 [3.80] - ILE222
C20 [3.76] - ILE222
C14 [3.73] -ILE223
C11 [3.84] - ILE223
C20 [3.56] - HIS225
C17 [3.66] - HIS225
C10 [3.75] - PHE247
C3 [3.54]- LEU315
C5 [3.83] -ALA316




C11 [3.70] - PHE491
C15 [3.85] -PHE491
C22 [3.76] -PHE491
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Table 3 Ligand Properties
Ligand Molar weight LogP H Acceptor H Donor pKa pKb logD logK TPSA
Arachidonic acid 303.46 6.16 2 1 4.82 0 3.99 −19.64 37.3
Anandamide 347.54 4.80 2 2 15.68 −0.39 4.80 −33.58 49.33
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anandamide, major residues were TYR 112, GLN 114,
PRO 118, ALA 126, ILE 222, ILE 223, SER 251, LEU
315, ALA 316 and PHE 491 (Figure 5B). The common
residues in both arachidonic acid and anandamide were
TYR 112, ILE 223, LEU 315, ALA 316 and PHE 491
(Table 2).
Evaluation of drug-likeness and ADME-Tox
Both arachidonic acid and anandamide were evaluated
for drug-likeness using Lipinski rule of five [36]. The
‘rule of five’ imposes limitation on the logP (the loga-
rithm of octanol/water partition coefficient), molecular
weight and the number of hydrogen bond acceptors and
donors. The rule states that most ‘drug-like’ molecules
have logP <5, molecular weight <500, number of hydro-
gen bond acceptors <10 and number of hydrogen bond
donors <5. Molecules violating more than one of theseTable 4 ADME-Tox prediction
ADME-Tox Arachidonic acid Anandamide
Solubilitya H2O (mg mL−1) 0.01 0.55
LogDb pH 1.7 (stomach) 6.75 6.18
LogDb pH 4.6 (duodenum) 6.57 6.18
LogDb pH 6.5 (jejunum, ileum) 5.14 6.18
LogDb pH 7.4 (blood) 4.26 6.18
LogDb pH 8.0 (colon) 3.69 6.18
% oral bioavailabilityc >30 >30
Absorptiond (cm s−1) 7.51x10−4 7.2x10−4
Distributione (L kg−1) 0.5 3.96
Ames testf 0.84 0.84
Prob. of Blood effectg 0.47 0.52
Prob. of Cardiovascular system effectg 0.07 0.30
Prob. of gastrointestinal system
effectg
0.04 0.07
Prob. of kidney effectg 0.69 0.75
Prob. of liver effectg 0.33 0.32
Prob. of lung effectg 0.79 0.70
aCalculates compound’s solubility in a buffer at a specified pH value.
bCalculates logarithm of the apparent octanol–water partition coefficient D
at various pH.
cEstimates the probability of a compounds bioavailability being above 30
and 70%.
dEstimates human jejunum permeability.
eCalculates the apparent volume of distribution for a compound in L kg-1.
fTest for assessing mutagenic properties of the compounds.
gEstimates probability of blood, gastrointestinal system, kidney, liver and
lung effect at therapeutic dose range.rules may have problems with bioavailability. Both ara-
chidonic acid and anandamide do not violate the
Lipinski rule of five parameters to be an orally active
compound (Table 3). Moreover, according to Freitas
[37], the oral bioavailability is inversely proportional to
topological polar surface area (TPSA). In this study, ara-
chidonic acid has lower topological surface area value than
anandamide suggesting arachidonic acid has better oral
bioavailability than anandamide. Analysis of pharmaco-
logical parameters using ADME-Tox evaluation revealed
that both arachidonic acid and anandamide have compar-
able values on specific parameters related to absorption,
distribution, metabolism, excretion and toxicity. But ara-
chidonic acid has less health effects on human than anan-
damide (Table 4).
Biological spectrum predictions
Computer software PASS [38,39] predicts simultan-
eously several hundreds of biological activities depend-
ing upon the chemical structures of compounds such asTable 5 Biological spectrum predictions of arachidonic
acid and anandamide
S.No Pa Pi Activities
1 0.784 0.020 Mucositis treatment
2 0.712 0.004 Antimutagenic
3 0.670 0.035 Antiviral
4 0.662 0.005 Antipyretic
5 0.623 0.099 Urologic disorders treatment
6 0.598 0.073 Antineoplastic (non-small cell lung cancer)
7 0.593 0.052 Antacid
8 0.584 0.054 Digestive functional disorders treatment
9 0.578 0.009 Antihelmintic (Nematodes)
10 0.562 0.051 Antineoplastic (gastric cancer)
11 0.556 0.115 Neuroprotector
12 0.555 0.004 Antiuremic
13 0.543 0.009 Acaricide
14 0.538 0.080 Antineurotoxic
15 0.536 0.117 Antineoplastic (head/neck cancer)
16 0.536 0.032 Anti-inflammatory, intestinal
17 0.526 0.038 Allergic conjunctivitis treatment
18 0.524 0.004 Antispirochetal
19 0.518 0.028 Cytoprotectant
20 0.512 0.008 Anticarcinogenic
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(Pa) and probable inactivity (Pi). Prediction of this
spectrum by PASS is based on SAR analysis of the train-
ing set containing more than 35,000 compounds, which
correlates with more than 500 kinds of biological activ-
ities. Pa and Pi values are independent and their values
can vary from 0 to 1.
The more the Pa value, the less is the probability of
false positives in the set of compounds selected for bio-
logical testing. For example, if one selects compounds
for which a particular activity has Pa ≥ 0.9, the expected
probability to find inactive compounds in the selected
set is very low, but about 90% of active compounds are
missed. If compounds with Pa ≥ 0.8 are chosen, the
probability to find inactive compounds is also low, but
about 80% of active compounds are missed. By default,
in PASS, value with Pa = Pi is chosen as a threshold and
all compounds with Pa > Pi are suggested to be active.
Another criterion for selection is the novelty of com-
pounds. If, Pa value is high, sometimes one may find
close analogues of known biologically active substances
among the tested compounds. For example, if, Pa > 0.7,
the chance to find the activity in experiment is high, but
in some cases the compound may occur to be the close
analogue of known pharmaceutical agents. If, 0.5 < Pa <
0.7 the chance to find the activity in experiment is less,
but the compound is not so similar to the known
pharmaceutical agents. If, Pa < 0.5 the chance to find the
activity in experiment is even less, but if it is confirmed
the compound may occur to be a new chemical entity.
Results of prediction of the biological spectrum of sub-
strates estimated when Pa > 0.5 is shown in Table 5. Both
the substrates show similar biological spectrum for anti-
carcinogenic activity.
Conclusion
The orphan human cytochrome P450 4X1 has been sug-
gested to be a potential drug target for cancer therapy.
Lack of the structural information about this enzyme
hinders the detailed characterization of its biological
functions and its applications in structure based design.
For this reason, the three-dimensional model of orphan
human cytochrome P450 4X1 was constructed using
homology modeling. To provide useful information to
characterize the enzyme’s function, two known sub-
strates, arachidonic acid and anandamide were docked
into the active sites and then refined by energy
minimization to determine favorable binding modes.
Several key residues TYR 112, ILE 223, LEU 315, ALA
316 and PHE 491 were identified to have involved in
binding of arachidonic acid and anandamide. These key
residues are expected to affect the catalytic activity and
can be used as candidates for further mutagenesis stud-
ies. Both the substrates does not violate Lipinski rule offive in drug-likeness test, while in ADME-Tox predic-
tion, arachidonic acid shows less health effects on car-
diovascular system, gastrointestinal system and kidney of
human when compared to anandamide. In biological ac-
tivity spectrum predictions, both arachidonic acid and
anandamide show anticarcinogenic activity. However, fur-
ther in-vivo validation and conformation of the present
finding is required. The results of this study will be useful
for structure-based drug design of orphan human cyto-
chrome P450 4X1.
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